Page 119 - Read Online

Page 10 of 12 Pegoraro et al. Hepatoma Res 2021;7:24 https://dx.doi.org/10.20517/2394-5079.2020.142

In conclusion, the case presented herein shows how the application of the right expertise, latest technologies
and techniques allows the safe management of patients with borderline resectable disease.

This report shows that laparoscopic RALPPS for the treatment of HCC on cirrhosis is a safe and feasible
procedure. ICG injection may provide additional information not only on the functional reserves but also
on guiding the transection phases during the minimally invasive approaches.

In our opinion, this procedure is a valid alternative to ALPPS and to open RALPPS, especially in cirrhotic
patients with expected high morbidity.

DECLARATIONS
Authors’ contributions
Conceived and designed the manuscript: Troisi RI
Wrote the manuscript: Pegoraro F, Montalti R
Critically revised the manuscript: Troisi RI, Giglio MC, Rompianesi G

Availability of data and materials
Data supporting our Report are deposited in our database and are available at request via contat with our
corresponding author.

Financial support and sponsorship
None.

Conflict of interest
The authors declare that they have no conflict of interests.

Ethical approval and consent to participate
At our Institution, the day before surgery all patients sign an informed consent which comprehends data
collection in anonymized form (video recording included), so no external ethical approval was necessary in
this case.

Consent for publication
Written informed consent was obtained from the patient before the first and the second surgery.

Copyright
© The Author(s) 2021.

REFERENCES
1. Burden of Disease Cancer C, Fitzmaurice C. Global, regional, and national cancer incidence, mortality, years of life lost, years lived
with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of
disease study. JAMA Oncol 2017;3:524-48. DOI PubMed PMC
2. EAftSot. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018;69:182-236. DOI PubMed
3. Hogemann D, Stamm G, Shin H, et al. Individual planning of liver surgery interventions with a virtual model of the liver and its
associated structures. Der Radiologe 2000;40:267-73. DOI PubMed
4. Zhang G, Zhou XJ, Zhu CZ, Dong Q, Su L. Usefulness of three-dimensional(3D) simulation software in hepatectomy for pediatric
hepatoblastoma. Surg Oncol 2016;25:236-43. DOI PubMed
5. Ho MC, Hasegawa K, Chen XP, et al. Surgery for intermediate and advanced hepatocellular carcinoma: a consensus report from the
5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014). Liver Cancer 2016;5:245-56. DOI PubMed PMC
6. Li PP, Wang ZH, Huang G, et al. Application of liver three-dimensional visualization technologies in the treatment planning of hepatic
malignant tumor. Zhonghua Wai Ke Za Zhi 2017;55:916-22. DOI PubMed
7. Oldhafer KJ, Donati M, Maghsoudi T, Ojdanic D, Stavrou GA. Integration of 3D volumetry, portal vein transection and in situ split
procedure: a new surgical strategy for inoperable liver metastasis. J Gastrointest Surg 2012;16:415-6. DOI PubMed